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A B S T R A C T
The myriad of neuropsychiatric manifestations reported in myotonic dystrophy type 1 may have its origin in
alterations of complex brain network interactions at the structural level. In this study, we tested the hypothesis
that altered white matter microstructural integrity and network organisation were present in a cohort of in-
dividuals with DM1 compared to unaffected controls, which was expected to be associated with CNS related
disease manifestations of DM1. We performed a cross-sectional neuropsychological assessment and brain MRI in
25 myotonic dystrophy type 1 (DM1) patients and 26 age, sex and educational level matched unaffected con-
trols. Patients were recruited from the Dutch cohort of the OPTIMISTIC study, a concluded trial which had
included ambulant, genetically confirmed DM1 patients who were severely fatigued. We applied graph theo-
retical analysis on structural networks derived from diffusion tensor imaging (DTI) data and deterministic
tractography to determine global and local network properties and performed group-wise comparisons.
Furthermore, we analysed the following variables from structural MRI imaging: semi-quantitative white matter
hyperintensity load andwhite matter tract integrity using tract-based spatial statistics (TBSS). Structural white
matter networks in DM1 were characterised by reduced global efficiency, local efficiency and strength, while the
network density was compatible to controls. Other findings included increased white matter hyperintensity load,
and diffuse alterations of white matter microstructure in projection, association and commissural fibres. DTI and
network measures were associated (partial correlations coefficients ranging from 0.46 to 0.55) with attention
(d2 Test), motor skill (Purdue Pegboard test) and visual-constructional ability and memory (copy subtest of the
Rey-Osterrieth Complex Figure Test). DTI and network measures were not associated with clinical measures of
fatigue (checklist individual strength, fatigue subscale) or apathy (apathy evaluation scale – clinician version). In
conclusion, our study supports the view of brain involvement in DM1 as a complex network disorder, char-
acterised by white matter network alterations that may have relevant neuropsychological correlations. This work
was supported by the European Community's Seventh Framework Programme (FP7/2007–2013; grant agree-
ment n° 305,697) and the Marigold Foundation.
1. Introduction
Myotonic dystrophy type 1 (DM1) is an hereditary chronic pro-
gressive multisystem disorder with autosomal dominant inheritance.
(Bird, 1993) Clinical features of central nervous system (CNS) in-
volvement in DM1 include cognitive deficits, psychiatric and behaviour
disturbances such as apathy, fatigue, and excessive daytime sleepiness.
These CNS symptoms are critical determinants of quality of life in DM1,
and some may be amenable to treatment. (Antonini et al., 2006;
Gagnon et al., 2008; Laberge et al., 2013; Okkersen et al., 2018) The
broad spectrum of clinical CNS involvement in DM1 is corroborated by
a variety of structural brain imaging abnormalities that are widely
dispersed throughout the brain, with apparently little anatomical spe-
cificity.(Cabada et al., 2017; Okkersen et al., 2017b; Sugiyama et al.,
2017) In particular, white matter involvement encompasses a combi-
nation increased white matter hyperintensity load and decreased mi-
crostructural integrity of white matter based on diffusion tensor ima-
ging (DTI) studies.(Minnerop et al., 2011; Zanigni et al., 2016)
Given the exceptionally large clinical variability of the disease, in
which the genetic defect exerts heterogeneous downstream effects in
virtually all cells of many different tissue types, these diverse and
widely dispersed structural imaging changes may come as no surprise.
(Harper, 2001) Despite the many structural imaging changes, attempts
at correlation with neuropsychological performance and other CNS
features have given inconsistent results.(Cabada et al., 2017; Minnerop
et al., 2011) Partly, this is explained by the variability of the disease in
combination with limited sample sizes.(Okkersen et al., 2017a) More-
over, cognitive and behavioural functions are not strictly anatomically
localised in particular brain regions, but have their origin in complex
network interactions.(Bressler and Menon, 2010; Wang et al., 2015) In
this respect, structural network analysis of white matter changes may
improve understanding of brain dysfunction in complex neurological
disorders with diffuse structural alterations, such as DM1.(Stam, 2014)
Structural connectivity of a network, consisting of brain regions (nodes)
and connecting white matter tracts (edges), can be obtained using
analysis of DTI followed by tractography.(Yan et al., 2011; Zalesky
et al., 2011) Graph theory, a branch of modern network theory, can
subsequently be used to characterise the properties of the network or-
ganisation.(Bullmore and Sporns, 2009) Previous research in diseases
that, like DM1, also have prominent white matter involvement (i.e.,
cerebral small-vessel disease) showed that white matter network al-
terations were an independent predictor of cognitive dysfunction and a
more sensitive measure than traditional magnetic resonance imaging
(MRI) measures.(Lawrence et al., 2014; Tuladhar et al., 2016) In this
study, we tested the hypothesis that altered white matter micro-
structural integrity and network organisation was present in a cohort of
individuals with DM1 compared to unaffected controls, which was ex-
pected to be associated with CNS related disease manifestations of
DM1.
2. Materials and methods
2.1. Participants
We performed a single-centre, cross-sectional study. Patients were
recruited from the Nijmegen subcohort (n=66) of the Observational
Prolonged Trial In Myotonic Dystrophy type 1 to Improve Quality of
Life- Standards, a Target Identification Collaboration (OPTIMISTIC)
study, a randomised trial in DM1 that investigated the effect of cogni-
tive behavioural therapy with optional graded exercise on capacity for
activity and participation.(Okkersen et al., 2018) This study recruited
adult, severely fatigued (as defined by a checklist individual strength
–fatigue subscale (CIS-fatigue) score≥ 35) patients that were able to
walk independently and had a genetically confirmed diagnosis of DM1;
details have been published elsewhere.(Okkersen et al., 2018; van
Engelen and Consortium, 2015). We invited patients to participate in
the current sub-study, only after they had finished participation in the
OPTIMISTIC main study. Specifically for this sub-study, we recruited 26
age-, sex- and educational level matched, unaffected, healthy, controls
from the social network of DM1 participants. We excluded relatives
unless they had been genetically tested for DM1 and the results of
testing were negative.We selected controls from the social network to
obtain a good match in terms of intelligence and social situation.
Controls were not evaluated for apathy, depression or fatigue with
questionnaires. This study was conducted in accordance with the pro-
visions of the Declaration of Helsinki and Good Clinical Practice
guidelines and the regional review board (CMO Arnhem-Nijmegen) of
our institution approved the study. All participants provided prior
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written informed consent.
2.2. Study overview and eligibility criteria
Assessment visits took place over two separate days for each parti-
cipant to reduce the influence of fatigue on (neuropsychological) tests.
On the first day, the following variables were recorded: age, sex, edu-
cational level according to the Dutch educational system (Duits A.
Kessels R., 2014) (7-point ordinal scale; 1= less than primary school,
7= academic degree). We excluded participants with significant
known co-morbidities of the central nervous system that could interfere
with neuropsychological or MRI-related outcomes by careful history
taking. In addition, we excluded significant (nocturnal) hypoventilation
by structured history taking for relevant symptoms (e.g. morning
headaches, nightmares, non-revitalizing sleep) and by performing
spirometry in supine and sitting position (patients were excluded if
functional vital capacity (FVC) showed a difference of ≥20% between
supine (lower value) and sitting position (higher value)), or a FVC<
60% of expected in sitting position. Patients with known nocturnal
hypoventilation who were stable on non-invasive ventilation were eli-
gible for the study. A family history was taken to exclude any hereditary
CNS diseases other than DM1. Following these procedures, participants
underwent brain MRI. On the second day, a neuropsychological as-
sessment was administered.
For further characterisation of our DM1 patient cohort, we utilised
clinical information previously recorded in the OPTIMISTIC study:
apathy (apathy evaluations scale, clinician version (AES-C)), capacity
for activity and social participation (DM1-Activ-c), overall disease im-
pact (myotonic dystrophy health index: MDHI), experienced fatigue
(checklist individual strength fatigue subscale: CIS-fatigue) and mus-
cular impairment (muscular impairment rating scale: MIRS) (Okkersen
et al., 2018). In addition, we recorded the disease classification based
on the age at onset of symptoms recorded in the OPTIMISTIC study (De
Antonio et al., 2016).
2.3. Neuropsychological assessment and analyses
A single neuropsychologist (MvD) administered the neuropsycho-
logical assessment for each participant, in a neutral low-stimulus en-
vironment. The assessment took approximately 90min. We selected
tests to minimize the influence of motor response as much as possible
and to evaluate cognitive function in seven different cognitive domains:
abstract reasoning, memory, executive functioning, fluency, attention,
visuospatial constructional abilities and psychomotor skill. We esti-
mated premorbid intelligence with the Dutch version of the National
Adult Reading Test (NART); abstract reasoning was evaluated with the
12-item short form of the Raven Progressive Matrices (RPM). Episodic
memory was evaluated with the Wechsler Memory Scale – Fourth
Edition (WMS-IV), subtests Logical Memory I and II (LMI and II); ex-
ecutive functioning was evaluated with the Trail Making Test (TMT),
the Stroop Color Word Test and the Brixton Spatial Anticipation Test.
We evaluated verbal fluency with the category fluency test (1-min an-
imal and occupation naming). We assessed attention using the d2 Test
by means of the total score on a subtest which corrected for the number
of incorrect answers. The Rey-Osterrieth Complex Figure Test(ROCF)
was used to evaluate visuospatial constructional abilities and visuos-
patial memory.(Shin et al., 2006) Finally, we administered the Purdue
Pegboard Test as a measure of psychomotor skill.(Tiffin and Asher,
1948) For the Pegboard Test, we calculated the mean score of the left
and right hand combined. We corrected the scores of some neu-
ropsychological tests to minimize the effects of deficits in motor skill
and dysarthria; we used these scores in subsequent between-group and
correlation analyses. For the TMT, we recorded the response time and
the number of correct answers on parts A and B and for each part
calculated a accuracy-speed trade-off score by dividing the accuracy by
the response time.(Schaapsmeerders et al., 2013) Then, we calculated
the TMT interference score: the accuracy-speed trade-off for TMT B
divided by the speed-accuracy trade-off for TMT-A.(Oosterman et al.,
2010) A similar procedure was followed for the Stroop cards I, II and III.
The Stroop interference score was calculated by dividing the accuracy-
speed trade-off for Stroop card III by the accuracy-speed trade-off for
Stroop Card II.(Raaphorst et al., 2011) Both interference scores were
used in the analyses to measure executive function. More detailed in-
formation about the neuropsychological tests can be found in Lezak
(2012).(Lezak, 2012)
2.4. MR imaging and analyses
2.4.1. MRI acquisition
MRI scans were acquired on a Siemens Magnetom TRIO 3 T scanner
(TIM trio, Siemens Medical Solutions, Erlangen, Germany). The pro-
tocol included a T1-weighted 3D magnetization-prepared rapid gra-
dient-echo (MPRAGE) imaging (TR/TE=1900/2.52ms, flip angle 9°;
voxel size 1.0×1.0×1.0mm, FOV=256mm), a T2 TSE (TR/
TE=3830/125ms, flip angle= 120°, voxel size 0.6×0.6×3mm,
FOV=240mm), a fluid-attenuated inversion recovery (FLAIR) se-
quence (TR/TE=9000/86ms, flip angle= 150°, voxel size
0.7×0.6× 5mm, FOV=240mm), and a Diffusion Tensor Imaging
(DTI) single-shot spin-echo EPI, b values 0 and 1000 s/mm2, TR/
TE=7400/71ms, number of encoding directions= 64,
FOV=240mm, and voxel size 2× 2×2mm and 8 b0 unweighted
images. All patients were scanned on the same MR scanner.
2.4.2. White matter hyperintensities
White matter hyperintensities (WMH) were evaluated semi-quanti-
tatively by an experienced neuroradiologist (F.M.) blinded for partici-
pant information. We defined a WMH as hyperintense signal on FLAIR
images with no or slight hypointensity on T1 weighted images. WMH
were scored using Fazekas' and age-related white matter changes scales
(ARWMC) and were determined for periventricular, deep and basal
ganglia white matter.(Fazekas et al., 1987; Wahlund et al., 2001).
2.4.3. DTI processing
First, we denoised the raw diffusion weighted images for each
participant using the Local Principal Component Analyses filter. We
then preprocessed the diffusion images using an in-house developed
Patching ArTefacts from Cardiac and Head motion (PATCH) algorithm
to correct for artefacts resulting from cardiac artefacts, head motion,
and eddy currents.(Zwiers, 2010) To eliminate echo planar imaging
(EPI) distortions, the EPI images were normalized to T1-images only in
the phase encoding direction.
We then applied DTIFIT from FSL to estimate the diffusion tensor
and basic DTI parameters, including fractional anisotropy (FA), mean
diffusivity (MD), axonal diffusivity (AD) and radial diffusivity (RD). The
estimated DTI parameters were fed into the tract-based spatial statistics
(TBSS) pipeline.(Smith et al., 2006) In short, this procedure creates a
common skeleton based on the mean normalized FA image, which re-
presents the core of the white matter tracts. All normalized FA, MD, AD
and RD images were projected onto this skeleton using the projections
factors. Mean DTI parameters were calculated within the skeleton.
2.4.4. Structural network construction
To define network nodes, brain regions were segmented by the
automated anatomical labelling (AAL) template, resulting in 45 regions
for each hemisphere, excluding the cerebellum.(Tzourio-Mazoyer et al.,
2002) Skull-stripped T1 images were non-linearly registered to the
Montreal Neurological Institute (MNI) 152 template using Functional
MRI of the Brain non-linear registration tool (FNIRT), part of the FSL
4.0.1 tools. The transformation matrix was derived from the registra-
tion of b0-images to T1 subject space using FLIRT and then used to
register the AAL image to each subject's diffusion image space. To de-
fine network edges, we performed whole brain deterministic
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tractography. Fibre tracking was undertaken using Diffusion Toolkit
(http://trackvis.org/dtk/). First, each voxel with a FA value> 0.2 was
seeded. Propagation of streamlines was estimated using the determi-
nistic fibre assignment by continuous tracking (FACT) algorithm. This
algorithm assumes uniform fibre orientation within voxels and sudden
changes in fibre tract orientation at each voxels' boundaries. Stream-
lines ended if: (1) fibre tracks left the brain mask, (2) the tracking
streamline encountered voxels with FA<0.2, or if (3) the turning angle
exceeded 45°. A network edge (or connection) between two brain re-
gions was assumed if the endpoints of a reconstructed streamline were
located within both regions. Network edge was weighted as a function
of the product of the number of streamlines between the brain regions
and mean FA of the streamlines.(Tuladhar et al., 2016) We normalized
edge weighting by the mean region volumes to correct for different
sizes of the brain regions and different brain sizes. This procedure
yielded an undirected, weighted 90×90 connectivity matrix for each
individual participant.
2.4.5. Graph theoretical analysis
We used the Brain Connectivity Toolbox to compute graph theore-
tical network measures.(Rubinov and Sporns, 2010) Calculated net-
work measures included density of a network, defined as the total
number of edges in a network divided by the possible number of edges,
and average network strength, defined as the mean sum of all weighted
edges for every node. To investigate the organisation of a network, we
calculated the global and local efficiency. Global efficiency is the
average inverse of the shortest path length, which is defined as the
minimum number of weighted connections between two regions in a
network. Local efficiency for a node is the global efficiency computed
on first-degree neighbours of that node. Global efficiency is related to
the extent of how well connected the brain regions are, while local
efficiency is a measure of how well connected local clusters of brain
regions are. To further characterise the constructed structural networks,
we estimated the rich club coefficient and compared these between
DM1 patients and unaffected controls.(van den Heuvel and Sporns,
2011) Rich clubs exist in a network, if certain nodes with a high degree,
thus rich in connections, are also more densely interconnected among
themselves than lower degree nodes in the network. We calculated the
rich club coefficients across a range of degree as the ratio of the sum of
the weighted connections between nodes of a certain degree and the
sum of weights of the strongest connections in the total network. Next,
we normalized the rich club coefficients, by dividing by the rich club
coefficients calculated on a set of simulated random networks of equal
size and degree distribution, to accommodate the fact that high degree
nodes have a higher probability of being interconnected by chance
alone. For these normalized coefficients, a rich club organisation was
present if the normalized value was> 1, thus larger than the coefficient
calculated for the random networks. We designated connections be-
tween rich club nodes as rich club connections, connections to rich club
nodes as feeder connections and connections between non-rich club
nodes as peripheral connections. For each type of connection, we cal-
culated the ‘connection strength’, a summary measure of connectivity,
by summing the edge weights for that type and compared these be-
tween DM1 patients and controls.
2.5. Statistical analyses
We used SPSS (Version 22.0. Armonk, NY: IBM Corp.) for all sta-
tistical analysis. We evaluated normality using the Shapiro-Wilk test.
Between group differences in demographics and neuropsychological
performance were evaluated using Chi-Square tests, independent t-tests
or Mann-Whitey U tests, as appropriate. For the neuropsychological
evaluation, we controlled the false discovery rate using the Benjamini-
Hochberg procedure, with false discovery rate Q set at 0.15.
(MacDonald, 2018) For the MRI analyses, we used likelihood ratio tests
for between-group comparisons of white matter hyperintensity load.
We used analysis of univariate general linear modelling to evaluate
differences in tissue volumes, whole-brain DTI parameters, and struc-
tural network measures, taking into account age, sex and education
level. In the between-group structural network comparison, we eval-
uated the effect of grey matter volumes by adding them as a covariate in
the linear models. For the TBSS analyses, we performed the voxel-wise
group comparison between DM1 patients and unaffected control sub-
jects, adjusted for age and sex, and voxel-wise associations between
skeletal DTI parameters and cognitive outcome measures within DM1
patients, while adjusting for age, sex and education. For this, we ap-
plied permutation-based statistical interference tool for non-parametric
approach (number of permutations is 5000) and significant clusters
were identified using the threshold-free cluster enhancement with a p-
value< .05, corrected for multiple comparisons.(Nichols and Holmes,
2002; Smith and Nichols, 2009) For the structural white matter net-
work analysis, we applied network-based statistics (NBS) to investigate
the location of network disruption.(Zalesky et al., 2010) A two-sample
t-test was performed with t-value threshold of 2.4 (corresponding to
p= .025 uncorrected), number of permutation testing set at 5000 and
family-wise error (p < .05) to correct for multiple comparisons. Fi-
nally, we performed exploratory analyses to investigate the associations
between neuropsychological, genetical and clinical measures with
global DTI and network measures in the patient group. We utilised
partial correlation, adjusting for age and education level into the model.
Table 1
Demographic and clinical parameters.
Variable DM1 patients Unaffected controls P-value
Sex, no. of men/women 13/15 15/11 0.785
Age, mean in years± SD 46.0 ± 9.0 50.2 ± 12.4 0.167
Educational level, mean ± SD 5.4 ± 1.0 5.4 ± 0.7 0.803
Functional vital capacity* (L), mean ± SD 3.3 (0.9) 4.4 (1.0) 0.0001
Estimated CTG progenitor allele length, mean ± SD ^ 250.12 ± 140.57 N/A N/A
Modal CTG repeat length, mean ± SD^ 441.84 ± 210.33 N/A N/A
Age at onset in years, mean ± SD^ 24.1 ± 12.1 N/A N/A
Clinical disease classification, no. (%) of patients with cDM1, iDM1, jDM1, aDM1, loDM1 0 (0), 1 (4), 12 (43), 12 (43), 2 (7)# N/A N/A
AES-c score^, mean ± SD 36.0 ± 7.9 N/A N/A
DM1-activ-c^, mean ± SD 65.5 ± 15.7 N/A N/A
CIS-fatigue^, mean ± SD 40.9 ± 7.5 N/A N/A
MDHI^, mean ± SD 26.4 ± 15.0 N/A N/A
MIRS score, no. (%) of patients^: 1/2/3/4/5 2 (7), 3 (11), 20 (71), 3 (11), 0 (0) N/A N/A
BDI-fs^ score, median [IQR] 2.0 [3.0] N/A N/A
^ Data collected in OPTIMISTIC main study; *sitting position. cDM1: congenital onset DM1; iDM1: infantile onset DM1, jDM1: juvenile onset DM1; aDM1 adult onset
DM1; loDM1: late-onset DM1.(De Antonio et al., 2016) #for one patient, age at onset of symptoms was unknown. AES-c: apathy evaluation scale, clinician version,
CIS-fatigue: checklist individual strength, fatigue subscale; MDHI: myotonic dystrophy health index; MIRS: muscular impairment rating scale; BDI-fs: Beck depression
inventory fast-screen.
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With regards to neuropsychological test performance, partial correla-
tions were only calculated for tests that showed significant between
group differences. Alpha was set at 0.05 (two-sided) for these analyses.
2.6. Data availability
The data that have given rise to the results from this trial, are
available on request via the corresponding author.
3. Results
3.1. Demographics and clinical characteristics
We included a total of 28 DM1 patients with a mean age of 46.0 [SD
9.0] and 26 age-matched unaffected controls with a mean age of 50.1
[SD 12.6] (Table 1). There were no statistically significant differences
in estimated intelligence and the demographical parameters between
groups. As expected, controls performed better on spirometry in com-
parison with DM1 patients (Table 1). For the MRI analysis, we ad-
ditionally excluded three DM1 patients because of contraindications to
MRI, a total of 25 DM1 patients underwent MRI. Of these 25 DM1
patients that underwent brain MRI, 16 and 9 had been in the standard
care and behavioural intervention groups of the OPTIMISTIC study,
respectively.
3.2. Neuropsychological assessment
The results of the neuropsychological assessment are presented in
Table 2. DM1 patients performed worse than controls on the Stroop
interference score (0.64 versus 0.70, p= .008), the d2 Test total score
corrected for false answers (334.0 versus 405.5, p= .0005), the ROCF
copy (30.0 versus 31.0, p= .037), ROCF immediate recall copy-cor-
rected version (0.63 versus 0.74, p= .040) and the Pegboard Test (8.3
versus 10.0, p= .009). Controlling the false discovery rate using the
Benjamini-Hochberg procedure, did not alter the significance of results.
3.3. MRI analyses
3.3.1. White matter hyperintensities
DM1 patients had higher WMH load expressed as Fazekas scores in
the periventricular and deep white matter in comparison to unaffected
controls (Table 3). In contrast, no difference were found for WMH in the
basal ganglia as determined by the ARWMC scale (Table 3).
3.3.2. Tract-based spatial statistics
We excluded two additional DM1 patients due to insufficient MRI
quality for DTI analysis, thus resulting in 23 DM1 patients and 26 un-
affected controls for the DTI analysis. Mean FA was significantly lower
in DM1 patients compared with unaffected controls; mean MD was
significantly higher in DM1 patients compared with healthy control
(Table 3). As shown in Fig. 1, lower FA values and higher, AD and RD
values were found in DM1 patients compared to unaffected controls and
were widely dispersed throughout the brain, in projection, association
and commissural fibre systems.
3.3.3. Structural white matter network analyses
In graph theoretical analysis, the structural networks of DM1 pa-
tients showed lower network strength, lower global efficiency and
lower local efficiency and a similar network density in comparison with
controls (Table 3). These results were not altered if grey matter volumes
were incorporated as a covariate in the analyses. In NBS analysis, we
found a subnetwork of reduced connection strength in DM1 patients
(p < .05) compared to controls (Fig. 2A). The reduced connections are
diffusely located, in line with DTI results. Normalized rich club coeffi-
cients were>1 in DM1 and controls and reflect the presence of rich
club organisation in both groups. Normalized rich club coefficients
were however reduced in DM1 patients compared to controls
(p < .001, 10.000 permutations). Group-wise analysis further in-
dicated significantly reduced rich club (RC, p= .03), feeder
(p < .0005) and peripheral connections (p= .001) in DM1 patients
compared to unaffected controls. Although visually, there is a trend of
more severe reduction in connection strength of rich club connections
than feeder or peripheral connections (Fig. 2B), we found no statisti-
cally significant differences in connection strength between the dif-
ferent connection types within the DM1 patient group (RC – feeder
connections (p= .50) and RC – peripheral connections (p= .11).
3.4. Correlation analyses
The results of exploratory, age and education corrected partial
correlation analyses between whole brain FA, MD, global and local
network efficiency and network strength, and neuropsychological tests
that demonstrated significant between-group differences resulted in
significant associations for the d2 Test and Purdue Pegboard Test, and
the ROCF – copy subtest, with absolute correlation coefficients ranging
from 0.458 to 0.554 (Table 4). No other significant correlations be-
tween DTI MRI parameters and neuropsychological performance were
found. We found no significant correlations between DTI and structural
Table 2
Neuropsychological test results in patients and controls: raw scores, p-values and effect sizes.
Cognitive test Dir. of score DM1 patients Mean (SD) or Median [IQR] Unaffected controls Mean (SD) or Median [IQR] P-Valueb Effect sizea
NART-IQ ↑ 97.2 (15.2) 98.7 (17.4) 0.741 0.1
RPM ↑ 8.6 (2.0) 9.5 (1.7) 0.083 0.5
LM I ↑ 31.0 [7.5] 27.5 [7.0] 0.202 0.3
LM II ↑ 26.6 (6.1) 24.4 (6.2) 0.183 0.4
Category fluency (animals) ↑ 27.4 (5.2) 25.9 (7.6) 0.400 0.2
Category fluency (occupations) ↑ 21.2 (4.2) 20.9 (6.3) 0.839 0.1
TMT Interference score ↑ 0.39 [0.11] 0.44 [0.15] 0.097 0.2
Stroop Color Word Test Interference score ↑ 0.64 [0.10] 0.70 [0.10] 0.008c 0.7
Brixton Spatial Anticipation Test ↓ 15.5 [5.5] 15.0 [9.0] 0.223 0.5
d2 test (Tn-F) ↑ 334.0 [86.5] 405.5 [129.0] 0.0005c 1.0
ROCF copy ↑ 30.0 [6.7] 31.0 [4.3] 0.037c 0.7
ROCF ir/copy ↑ 0.63 [0.28] 0.74 [0.19] 0.040c 0.5
ROCF dr/copy ↑ 0.65 [0.27] 0.75 [0.21] 0.100 0.4
Pegboard ↑ 8.3 [5.5] 10.0 [2.5] 0.009c 0.9
dir: direction; NART: National adult reading test – IQ estimate; RPM: Raven's progressive matrices; LM I and LM II: Logical Memory of WSM-IV; ROCF: Rey-Osterrieth
Complex Figure Test; IQR: interquartile range.
a Cohen's d is used as a measure of effect size, provided is the absolute effect size.
b Calculated using independent t-tests and non-parametric Mann-Whitney U tests for normally and non-normally distributed data. p-values< .05 are bold.
c All results remained significant after application of the Benjamini-Hochberg procedure with false-discovery rate Q set at 0.15.
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network measures and clinical scales: CIS-fatigue and AES-c. No cor-
relations were found between DTI and structural network measures and
estimated CTG repeat expansion size (modal and estimated progenitor
allele size). Finally, we found no significant associations between DTI
and structural network measures and age at onset after adjustment for
age and grey matter volume.
4. Discussion
In this cross-sectional study, we demonstrate alterations in struc-
tural white matter networks in DM1 patients compared to unaffected
controls. In comparison to unaffected controls, the networks in DM1 are
characterised by reduced network strength combined with reduced
global and local efficiency at a comparable network density. Thus, al-
though the number of connections in the network of DM1 patients is not
Table 3
MRI analyses.
DM1 Unaffected controls p-value
White matter lesion loada N=24 N=26
Fazekas: periventricular white matter 2 ± 0.76 0.92 ± 0.56 p < .0001
mean ± SD, score 0/1/2/3 0 / 7 / 11 / 7 5 / 18 / 3 / 0
Fazekas: deep white matter 1.16 ± 0.69 0.58 ± 0.50 p < .0001
mean ± SD, score 0/1/2/3 3 / 16 / 5 /1 11 / 15 / 0 / 0
ARWMC 1.6 ± 0.65 0.54 ± 0.51 p < .0001
mean ± SD, score 0/1/2/3 0 / 12 / 11 / 2 12 / 14 / 0 / 0
ARWMC basal ganglia 0.28 ± 0.61 0.19 ± 0.58 p=0.539
mean ± SD, score 0/1/2/3 20 / 3 / 2 / 0 23 / 1 / 2 / 0
Volumetryb N=23 N=26
Average grey matter volume – mean (SD) 619.8 (78.9) 690.6 (81.8) p=0.0005
Average white matter volume – mean (SD) 453.4 (58.4) 465.8 (61.9) p=0.611
Average CSF volume – mean (SD) 406.9 (91.7) 416.1 (62.4) p=0.660
Diffusion tensor imagingb N=23 N=26
FA – mean (SD) 0.50 (0.02) 0.56 (0.02) p < 0.0001
MD – mean (SD) 0.08e−2 (0.03e−3) 0.07e−2 (0.03e−3) p < 0.0001
Structural white matter networksb N=22 N=22
Density – mean (SD) 0.0985 (0.00537) 0.0973 (0.00335) p=0.312
Strength – mean (SD) 0.0383 (0.01238) 0.0509 (0.00887) p < 0.0001
Global efficiency – mean (SD) 0.0023 (0.00072) 0.0031 (0.00053) p < 0.0001
Local efficiencyc−mean (SD) 0.0019 (0.00054) 0.0025 (0.00041) p < 0.0001
White-matter hyperintensities in DM1 patients and control as measured with Fazekas and ARWMC scales.
a Likelihood ratio test.
b univariate GLM analysis p-value after correction for age, sex and educational level.
c Mean average across nodes.
Fig. 1. TBSS results. Differences for FA (red, A), MD (blue, B), between DM1 patients and unaffected controls. For both FA and MD, between-group differences can be
seen widely dispersed throughout the brain and present in association, projection and commissural fibre systems (p < 0.05, corrected for multiple comparisons).
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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different from unaffected controls, the alterations in efficiency and
strength are indicative of differences in structural network organisa-
tion. Although the presence of a rich-club (RC) organisation was present
in both groups, normalized RC coefficients were reduced in DM1 pa-
tients in comparison to controls, signalling weaker connections between
these nodes. A weaker connected rich club, the core of the connectome
through which many network paths pass, may lead to a longer shortest
path length overall within a network and hence, a network that is less
integrated and less efficient at the global level.(Dennis et al., 2013)
Furthermore, our results indicate that not only rich club connections,
but also the feeder and peripheral connections have decreased strength
in comparison with controls, indicating widespread structural altera-
tions in the white matter networks. These diffuse network changes align
with the diverse and anatomically unspecific structural changes in grey
and white matter, such as grey matter volume reductions and alteration
in white matter tract integrity in the current and in previous studies, as
discussed below.(Antonini et al., 2004; Cabada et al., 2017)
This study on structural white matter networks may be considered
in the context of four other DM1 studies evaluating MRI derived brain
networks that were recently published (a structured summary of find-
ings is given in Supplemental Table S1). Graph theoretical measures of
global and local connectivity in structural grey matter networks in 28
DM1 patients were not different from 28 unaffected controls, although
there were regional differences in anatomical hub distribution, in-
dicating topologically different networks.(Sugiyama et al., 2017) Other
DM1 MRI network studies in DM1 patients constitute functional resting-
state MRI (rs-fMRI) studies, performed by one group of authors (Sup-
plemental Table S1).(Serra et al., 2016a; Serra et al., 2016b; Serra et al.,
2014) Graph theoretical network analyses of rs-fMRI did not reveal any
changes in global network connectivity measures.(Serra et al., 2016a;
Serra et al., 2016b) Both studies, carried out in partly overlapping co-
horts, did report changes in local connectivity, such as nodal degree and
efficiency, across different brain regions.(Serra et al., 2016a; Serra
et al., 2016b) Although different data sources and analyses methods
preclude direct comparisons, these and our network studies together
demonstrate that the pathophysiological processes in DM1 consistently
lead to changes in both structural and functional networks. They sup-
port the view of brain involvement in DM1 as ‘a complex network
disorder’.
We hypothesized that DTI and structural network measures would
be associated with neuropsychological performance, in particular of
neuropsychological tests that are often abnormal in DM1 patients such
Fig. 2. White matter networks in DM1 patients versus controls. I. Topological cluster that significantly differed between DM1 patients and unaffected controls (p-
value adjusted< 0.05, threshold t=2.4 (corresponding with p-uncorrected 0.025). Networks were projected on the MNI152 standard space template, and visualized
from the axial plane in neurological convention using the BrainNet Viewer toolbox in MATLAB.(Xia et al., 2013) a: anterior, p: posterior, r: right, l: left. Panel A: left
lateral view. Panel B: Axial view from top. Panel C: right lateral view. II. Connection strength of rich club, feeder and peripheral connections of DM1 patients relative
controls. Connections strength in DM1 patients was lower than in controls (see text); there were no statistically significant differences in connection strength between
the 3 connection types within the DM1 patient group.
Table 4
Partial correlations between DTI and network parameters and neuropsychological performance in DM1 patients.
FA MD Global network efficiency Local network efficiency Network strength
Stroop Interference score 0.070 (0.770) −0.176 (0.459) 0.214 (0.365) 0.199 (0.401) 0.201 (0.395)
d2 Test 0.549 (0.012)* −0.554 (0.011)* 0.535 (0.015)* 0.465(0.039)* 0.548 (0.012)*
ROCF - Copy 0.416 (0.068) −0.475 (0.034)* 0.055 (0.817) 0.115 (0.628) 0.057 (0.811)
ROCF - Immediate recall (IR), copy corrected −0.318 (0.172) 0.291 (0.213) −0.167 (0.482) −0.174 (0.463) −0.195 (0.409)
Pegboard Test 0.549 (0.012)* −0.404 (0.078) 0.462 (0.041)* 0.458 (0.042)* 0.482 (0.032)*
Depicted are the partial correlation coefficients (r) with the corresponding uncorrected p-values in parentheses. Correlation coefficients are corrected for age and
level of education. FA: fractional anisotropy; MD: mean diffusivity; CWT: color-word test ROCF: Rey-Osterrieth Complex Figure.
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as the ROCF-copy test.(Okkersen et al., 2017a; Sistiaga et al., 2010;
Weber et al., 2010; Zalonis et al., 2010) In our study, out of the five
tests that showed group effects, only the test for attention (d2 Test) and
motor skill (Purdue Pegboard) are significantly associated with struc-
tural network measures. Notably, the correlation coefficients of net-
work-based measures for these tests were not higher than those for the
averaged whole-brain FA or MD values. Also, both tests are critically
dependent on motor function that is expected to be compromised in
DM1. The relative lack of associations between structural white matter
network measures and other neuropsychological measures is remark-
able, given that white matter network disruptions comparable to those
observed in our study have been found to be associated with cognitive
deficits in other disorders characterised by white matter damage, such
as multiple sclerosis and cerebral small-vessel disease.(Lawrence et al.,
2014; Llufriu et al., 2017; Tuladhar et al., 2016) More than one factor
may contribute to the relative lack of associations between network
measures and neuropsychological performance in our study. The dif-
ferences in neuropsychological performance between the patient and
control group are relatively small in our sample of DM1 patients. De-
spite diffuse alterations in brain structure, the brain in DM1 seems to be
able to upkeep neuropsychological performance to some extent, pos-
sibly as a results of unknown compensatory mechanisms. Furthermore,
functional network connectivity or decoupling between functional-
structural connectivity, not assessed in this study, might be an im-
portant factor determining cognitive performance in DM1 patients.
(Serra et al., 2016b) Finally, it may be explained by the small sample
size and related statistical power issues in comparison to studies in
other disorders. Similar reasons may explain the lack of associations
between structural white matter network measures and measures of
apathy and experienced fatigue.
In the ‘conventional’ MRI analysis, our results demonstrating in-
creased white matter hyperintensity load and widespread alterations in
white matter tract integrity corroborate earlier work and are indicative
of widespread involvement of white matter tracts (Baldanzi et al., 2016;
Minnerop et al., 2011; Zanigni et al., 2016). Possible neuropathological
correlates of these white matter changes include loss of axons and/or
myelin, capillary hyalinization and fibrillary gliosis, although these is
scarce literature on human brain white matter histopathology in DM1.
(Gourdon and Meola, 2017; Itoh et al., 2010) Future studies should
preferably include in vivo white matter imaging combined with post-
mortem histopathological observations.
This study has several limitations. We recruited DM1 patients that
had previously participated in the OPTIMISTIC trial, who performed
relatively well on the neuropsychological assessment, had relatively
high levels of education, and were motivated to participate in clinical
research. Consequently, the individuals in our study could be argued to
be a relatively lesser cognitively affected sample of the DM1 popula-
tion, as supported effect sizes on neuropsychological tests mostly
smaller than those estimated in a recent meta-analysis.(Okkersen et al.,
2017a) Generalisability of our findings may also be limited by the se-
lection of DM1 patients in OPTIMISTIC that were severely fatigued as
defined by a checklist individual strength fatigue subscale score of
≥35. However, severe fatigue as defined by this criterion occurs in 70%
of the DM1 population.(Kalkman et al., 2005) Furthermore, because of
the cross-sectional design of MRI sub-study, we cannot infer possible
effects of the OPTIMISTIC behavioural intervention on structural white
matter networks. Finally, we did not evaluate controls for depression of
anxiety, although these symptoms may have been present as a result of
a the emotional and social burden of a chronic disease of a family
member or close friend.
The reader should note that TBSS, although a robust method for
white matter analysis, may have a less than desired anatomical speci-
ficity. The use of the traditional ‘mean FA image’ method, which dis-
cards the directional information of the tensor in the skeleton con-
struction step, may compromise the anatomical specificity of TBSS.
(Bach et al., 2014) Construction of the FA skeleton may also be less
alignment invariant than assumed and the projection step onto the FA
skeleton may also vary in quality, especially in disease states such as
DM1, where there are concurrent changes in brain morphology.(Bach
et al., 2014; Keihaninejad et al., 2012) These limitations of TBSS ne-
cessitate cautious interpretation of results. With regards to the measures
of the white matter structural network, these may be dependent on the
fibre tracking algorithm and the choice of the anatomical labelling to
define network nodes, as well as on network density.(Duda et al., 2014)
It would be interesting to see if probabilistic and deterministic fibre
tracking algorithms provide similar results on structural networks. Fu-
ture research may include the cerebellum, which is of potential interest
in DM1 (Minnerop et al., 2018); it was excluded in the current study as
the deterministic tracking algorithm we utilised is potentially less ac-
curate with cerebellar connections.Furthermore, network-based statis-
tics may be influenced by the choice of the threshold, as explained
previously.(Zalesky et al., 2010) Finally, the correlation analyses
should be considered exploratory given the undertaking of a large
number of statistical tests. The findings in the current study therefore
warrant independent replication in further studies. Future imaging re-
search in larger (multinational) clinically and/or genetically stratified
DM1 cohorts with a prospective design could combine structural and
functional imaging techniques and incorporate possible clinical corre-
lates not evaluated here, such as personality traits and psychiatric
symptoms.
Funding
Funded by the European Community's Seventh Framework
Programme (FP7/2007–2013; grant agreement n° 305697) and the
Marigold Foundation. The funders of this trial had no role in the study
design, data collection, analysis, interpretation of data, writing the re-
port, or decisions regarding when to submit publications.
Authors' competing interests
Ms. van Dorst has no competing interests to disclose.
Mr. Okkersen has no competing interests to disclose.
Dr. Meijer has no competing interests to disclose.
Professor Kessels has no competing interests to disclose.
Professor Monckton has been a paid scientific consultant and/or
received an honoraria from Biogen Idec, AMO Pharma, Charles River
and Vertex Pharmaceuticals. Professor Monckton also had a research
contract with AMO Pharma and has received awards from the European
Union, Muscular Dystrophy UK and the Myotonic Dystrophy Support
Group.
Professor Van Engelen reports grant support from the European
Union FP-7 program (OPTIMISTIC) and Marigold Foundation.
Dr. Tuladhar reports grants from Junior Staff Member Dutch Heart
Foundation 2016 T044.
Dr. Raaphorst reports grant support from the Marigold Foundation.
Author contributions
This study was conceptualized by KO, JR and AT. All authors were
involved in the design of the study and preparation of the manuscript.
Statistical analysis performed by MD and AT. The first and second au-
thors wrote the first draft of this manuscript. All authors attest to the
completeness and accuracy of data and corresponding analyses.
External Advisory board
Dr. Marie Kierkegaard (Karolinska Instituet Medical University,
Huddinge, Sweden).
M. van Dorst et al. NeuroImage: Clinical 21 (2019) 101615
8
Authors' competing interests
Ms. van Dorst has no competing interests to disclose; Mr. Okkersen
has no competing interests to disclose; Dr. Meijer has no competing
interests to disclose; Professor Kessels has no competing interests to
disclose; Professor Monckton has been a paid scientific consultant and/
or received an honoraria from Biogen Idec, AMO Pharma, Charles River
and Vertex Pharmaceuticals. Professor Monckton also had a research
contract with AMO Pharma and has received awards from the European
Union, Muscular Dystrophy UK and the Myotonic Dystrophy Support
Group; Professor Van Engelen reports grant support from the European
Union FP-7 program (OPTIMISTIC) and Marigold Foundation; Dr.
Tuladhar reports grants from Junior Staff Member Dutch Heart
Foundation 2016 T044; Dr. Raaphorst reports grant support from the
Marigold Foundation.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2018.101615.
References
Antonini, G., Mainero, C., Romano, A., Giubilei, F., Ceschin, V., Gragnani, F., Morino, S.,
Fiorelli, M., Soscia, F., Di Pasquale, A., Caramia, F., 2004. Cerebral atrophy in
myotonic dystrophy: a voxel based morphometric study. J. Neurol. Neurosurg.
Psychiatry 75, 1611–1613.
Antonini, G., Soscia, F., Giubilei, F., De Carolis, A., Gragnani, F., Morino, S., Ruberto, A.,
Tatarelli, R., 2006. Health-related quality of life in myotonic dystrophy type 1 and its
relationship with cognitive and emotional functioning. J. Rehabil. Med. 38, 181–185.
Bach, M., Laun, F.B., Leemans, A., Tax, C.M., Biessels, G.J., Stieltjes, B., Maier-Hein, K.H.,
2014. Methodological considerations on tract-based spatial statistics (TBSS).
NeuroImage 100, 358–369.
Baldanzi, S., Cecchi, P., Fabbri, S., Pesaresi, I., Simoncini, C., Angelini, C., Bonuccelli, U.,
Cosottini, M., Siciliano, G., 2016. Relationship between neuropsychological impair-
ment and grey and white matter changes in adult-onset myotonic dystrophy type 1.
Neuroimage Clin. 12, 190–197.
Bird, T.D., 1993. Myotonic dystrophy type 1. In: Pagon, R.A., Adam, M.P., Ardinger, H.H.,
Wallace, S.E., Amemiya, A., Bean, L.J.H., Bird, T.D., Dolan, C.R., Fong, C.T., Smith,
R.J.H., Stephens, K. (Eds.), GeneReviews(R), Seattle (WA).
Bressler, S.L., Menon, V., 2010. Large-scale brain networks in cognition: emerging
methods and principles. Trends Cogn. Sci. 14, 277–290.
Bullmore, E., Sporns, O., 2009. Complex brain networks: graph theoretical analysis of
structural and functional systems. Nat. Rev. Neurosci. 10, 186–198.
Cabada, T., Iridoy, M., Jerico, I., Lecumberri, P., Seijas, R., Gargallo, A., Gomez, M., 2017.
Brain involvement in myotonic dystrophy type 1: a Morphometric and diffusion
tensor imaging study with neuropsychological correlation. Arch. Clin. Neuropsychol.
32, 401–412.
De Antonio, M., Dogan, C., Hamroun, D., Mati, M., Zerrouki, S., Eymard, B., Katsahian, S.,
Bassez, G., French Myotonic Dystrophy Clinical, 2016. Unravelling the myotonic
dystrophy type 1 clinical spectrum: a systematic registry-based study with implica-
tions for disease classification. Rev. Neurol. (Paris) 172, 572–580.
Dennis, E.L., Jahanshad, N., Toga, A.W., McMahon, K.L., de Zubicaray, G.I., Hickie, I.,
Wright, M.J., Thompson, P.M., 2013. Development of the "Rich Club" in brain con-
nectivity networks from 438 adolescents & adults aged 12 to 30. Proc. IEEE Int Symp
Biomed Imaging 624–627.
Duda, J.T., Cook, P.A., Gee, J.C., 2014. Reproducibility of graph metrics of human brain
structural networks. Front Neuroinform 8, 46.
Duits, A., Kessels, R., 2014. Schatten van het premorbide functioneren [estimating pre-
morbid intelligence]. In: Hendriks, M., Kessels, R., Gorissen, M., Schmand, B., Duits,
A. (Eds.), Neuropsychologische Diagnostiek: de klinische praktijk. Boom, Amsterdam,
pp. 173–186.
Fazekas, F., Chawluk, J.B., Alavi, A., Hurtig, H.I., Zimmerman, R.A., 1987. MR signal
abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am. J.
Roentgenol. 149, 351–356.
Gagnon, C., Mathieu, J., Jean, S., Laberge, L., Perron, M., Veillette, S., Richer, L., Noreau,
L., 2008. Predictors of disrupted social participation in myotonic dystrophy type 1.
Arch. Phys. Med. Rehabil. 89, 1246–1255.
Gourdon, G., Meola, G., 2017. Myotonic Dystrophies: State of the Art of New Therapeutic
Developments for the CNS. Front. Cell. Neurosci. 11, 101.
Harper, P.S., 2001. Myotonic Dystrophy, 3rd ed. W.B. Saunders, London.
Itoh, K., Mitani, M., Kawamoto, K., Futamura, N., Funakawa, I., Jinnai, K., Fushiki, S.,
2010. Neuropathology does not Correlate with Regional differences in the Extent of
expansion of CTG Repeats in the Brain with Myotonic Dystrophy Type 1. Acta
Histochem. Cytochem. 43, 149–156.
Kalkman, J.S., Schillings, M.L., van der Werf, S.P., Padberg, G.W., Zwarts, M.J., van
Engelen, B.G., Bleijenberg, G., 2005. Experienced fatigue in facioscapulohumeral
dystrophy, myotonic dystrophy, and HMSN-I. J. Neurol. Neurosurg. Psychiatry 76,
1406–1409.
Keihaninejad, S., Ryan, N.S., Malone, I.B., Modat, M., Cash, D., Ridgway, G.R., Zhang, H.,
Fox, N.C., Ourselin, S., 2012. The importance of group-wise registration in tract based
spatial statistics study of neurodegeneration: a simulation study in Alzheimer's dis-
ease. PLoS One 7, e45996.
Laberge, L., Mathieu, J., Auclair, J., Gagnon, E., Noreau, L., Gagnon, C., 2013. Clinical,
psychosocial, and central correlates of quality of life in myotonic dystrophy type 1
patients. Eur. Neurol. 70, 308–315.
Lawrence, A.J., Chung, A.W., Morris, R.G., Markus, H.S., Barrick, T.R., 2014. Structural
network efficiency is associated with cognitive impairment in small-vessel disease.
Neurology 83, 304–311.
Lezak, M.D., 2012. Neuropsychological Assessment, 5th ed. Oxford University Press,
Oxford; New York.
Llufriu, S., Martinez-Heras, E., Solana, E., Sola-Valls, N., Sepulveda, M., Blanco, Y.,
Martinez-Lapiscina, E.H., Andorra, M., Villoslada, P., Prats-Galino, A., Saiz, A., 2017.
Structural networks involved in attention and executive functions in multiple
sclerosis. Neuroimage Clin 13, 288–296.
MacDonald, J.H., 2018. Handbook of Biological Statistics.
Minnerop, M., Weber, B., Schoene-Bake, J.C., Roeske, S., Mirbach, S., Anspach, C.,
Schneider-Gold, C., Betz, R.C., Helmstaedter, C., Tittgemeyer, M., Klockgether, T.,
Kornblum, C., 2011. The brain in myotonic dystrophy 1 and 2: evidence for a pre-
dominant white matter disease. Brain 134, 3530–3546.
Minnerop, M., Gliem, C., Kornblum, C., 2018. Current Progress in CNS Imaging of
Myotonic Dystrophy. Front. Neurol. 9, 646.
Nichols, T.E., Holmes, A.P., 2002. Nonparametric permutation tests for functional neu-
roimaging: a primer with examples. Hum. Brain Mapp. 15, 1–25.
Okkersen, K., Buskes, M., Groenewoud, J., Kessels, R.P.C., Knoop, H., van Engelen, B.,
Raaphorst, J., 2017a. The cognitive profile of myotonic dystrophy type 1: a sys-
tematic review and meta-analysis. Cortex 95, 143–155.
Okkersen, K., Monckton, D.G., Le, N., Tuladhar, A.M., Raaphorst, J., van Engelen, B.G.M.,
2017b. Brain imaging in myotonic dystrophy type 1: a systematic review. Neurology
89, 960–969.
Okkersen, K., Jimenez-Moreno, C., Wenninger, S., Daidj, F., Glennon, J., Cumming, S.,
Littleford, R., Monckton, D.G., Lochmuller, H., Catt, M., Faber, C.G., Hapca, A.,
Donnan, P.T., Gorman, G., Bassez, G., Schoser, B., Knoop, H., Treweek, S., van
Engelen, B.G.M., Consortium, O., 2018. Cognitive behavioural therapy with optional
graded exercise therapy in patients with severe fatigue with myotonic dystrophy type
1: a multicentre, single-blind, randomised trial. Lancet Neurol. 17 (8), 671–680.
Oosterman, J.M., Vogels, R.L., van Harten, B., Gouw, A.A., Poggesi, A., Scheltens, P.,
Kessels, R.P., Scherder, E.J., 2010. Assessing mental flexibility: neuroanatomical and
neuropsychological correlates of the Trail making Test in elderly people. Clin.
Neuropsychol. 24, 203–219.
Raaphorst, J., de Visser, M., van Tol, M.J., Linssen, W.H., van der Kooi, A.J., de Haan,
R.J., van den Berg, L.H., Schmand, B., 2011. Cognitive dysfunction in lower motor
neuron disease: executive and memory deficits in progressive muscular atrophy. J.
Neurol. Neurosurg. Psychiatry 82, 170–175.
Rubinov, M., Sporns, O., 2010. Complex network measures of brain connectivity: uses and
interpretations. NeuroImage 52, 1059–1069.
Schaapsmeerders, P., Maaijwee, N.A., van Dijk, E.J., Rutten-Jacobs, L.C., Arntz, R.M.,
Schoonderwaldt, H.C., Dorresteijn, L.D., Kessels, R.P., de Leeuw, F.E., 2013. Long-
term cognitive impairment after first-ever ischemic stroke in young adults. Stroke 44,
1621–1628.
Serra, L., Silvestri, G., Petrucci, A., Basile, B., Masciullo, M., Makovac, E., Torso, M.,
Spano, B., Mastropasqua, C., Harrison, N.A., Bianchi, M.L., Giacanelli, M.,
Caltagirone, C., Cercignani, M., Bozzali, M., 2014. Abnormal functional brain con-
nectivity and personality traits in myotonic dystrophy type 1. JAMA Neurol 71,
603–611.
Serra, L., Cercignani, M., Bruschini, M., Cipolotti, L., Mancini, M., Silvestri, G., Petrucci,
A., Bucci, E., Antonini, G., Licchelli, L., Spano, B., Giacanelli, M., Caltagirone, C.,
Meola, G., Bozzali, M., 2016a. "I know that you know that I know": Neural Substrates
Associated with Social Cognition Deficits in DM1 patients. PLoS One 11, e0156901.
Serra, L., Mancini, M., Silvestri, G., Petrucci, A., Masciullo, M., Spano, B., Torso, M.,
Mastropasqua, C., Giacanelli, M., Caltagirone, C., Cercignani, M., Meola, G., Bozzali,
M., 2016b. Brain Connectomics' Modification to Clarify Motor and Nonmotor
Features of Myotonic Dystrophy Type 1. Neural Plast, 2696085. https://www.
hindawi.com/journals/np/2016/2696085/.
Shin, M.S., Park, S.Y., Park, S.R., Seol, S.H., Kwon, J.S., 2006. Clinical and empirical
applications of the Rey-Osterrieth complex Figure Test. Nat. Protoc. 1, 892–899.
Sistiaga, A., Urreta, I., Jodar, M., Cobo, A.M., Emparanza, J., Otaegui, D., Poza, J.J.,
Merino, J.J., Imaz, H., Marti-Masso, J.F., Lopez De Munain, A., 2010. Cognitive/
personality pattern and triplet expansion size in adult myotonic dystrophy type 1
(DM1): CTG repeats, cognition and personality in DM1. Psychol. Med. 40, 487–495.
Smith, S.M., Nichols, T.E., 2009. Threshold-free cluster enhancement: addressing pro-
blems of smoothing, threshold dependence and localisation in cluster inference.
NeuroImage 44, 83–98.
Smith, S.M., Jenkinson, M., Johansen-Berg, H., Rueckert, D., Nichols, T.E., MacKay, C.E.,
Watkins, K.E., Ciccarelli, O., Cader, M.Z., Matthews, P.M., Behrens, T.E., 2006. Tract-
based spatial statistics: voxelwise analysis of multi-subject diffusion data.
NeuroImage 31, 1487–1505.
Stam, C.J., 2014. Modern network science of neurological disorders. Nat. Rev. Neurosci.
15, 683–695.
Sugiyama, A., Sone, D., Sato, N., Kimura, Y., Ota, M., Maikusa, N., Maekawa, T.,
Enokizono, M., Mori-Yoshimura, M., Ohya, Y., Kuwabara, S., Matsuda, H., 2017.
Brain gray matter structural network in myotonic dystrophy type 1. PLoS One 12,
e0187343.
Tiffin, J., Asher, E.J., 1948. The Purdue pegboard; norms and studies of reliability and
validity. J. Appl. Psychol. 32, 234–247.
M. van Dorst et al. NeuroImage: Clinical 21 (2019) 101615
9
Tuladhar, A.M., van Dijk, E., Zwiers, M.P., van Norden, A.G., de Laat, K.F., Shumskaya, E.,
Norris, D.G., de Leeuw, F.E., 2016. Structural network connectivity and cognition in
cerebral small vessel disease. Hum. Brain Mapp. 37, 300–310.
Tzourio-Mazoyer, N., Landeau, B., Papathanassiou, D., Crivello, F., Etard, O., Delcroix, N.,
Mazoyer, B., Joliot, M., 2002. Automated anatomical labeling of activations in SPM
using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.
NeuroImage 15, 273–289.
van den Heuvel, M.P., Sporns, O., 2011. Rich-club organization of the human con-
nectome. J. Neurosci. 31, 15775–15786.
van Engelen, B., Consortium, O., 2015. Cognitive behaviour therapy plus aerobic exercise
training to increase activity in patients with myotonic dystrophy type 1 (DM1)
compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial.
Trials 16, 224.
Wahlund, L.O., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjogren, M., Wallin, A.,
Ader, H., Leys, D., Pantoni, L., Pasquier, F., Erkinjuntti, T., Scheltens, P., European
Task Force on Age-Related White Matter, 2001. A new rating scale for age-related
white matter changes applicable to MRI and CT. Stroke 32, 1318–1322.
Wang, Z., Dai, Z., Gong, G., Zhou, C., He, Y., 2015. Understanding structural-functional
relationships in the human brain: a large-scale network perspective. Neuroscientist
21, 290–305.
Weber, Y.G., Roebling, R., Kassubek, J., Hoffmann, S., Rosenbohm, A., Wolf, M.,
Steinbach, P., Jurkat-Rott, K., Walter, H., Reske, S.N., Lehmann-Horn, F., Mottaghy,
F.M., Lerche, H., 2010. Comparative analysis of brain structure, metabolism, and
cognition in myotonic dystrophy 1 and 2. Neurology 74, 1108–1117.
Xia, M., Wang, J., He, Y., 2013. BrainNet Viewer: a network visualization tool for human
brain connectomics. PLoS One 8, e68910.
Yan, C., Gong, G., Wang, J., Wang, D., Liu, D., Zhu, C., Chen, Z.J., Evans, A., Zang, Y., He,
Y., 2011. Sex- and brain size-related small-world structural cortical networks in
young adults: a DTI tractography study. Cereb. Cortex 21, 449–458.
Zalesky, A., Fornito, A., Bullmore, E.T., 2010. Network-based statistic: identifying dif-
ferences in brain networks. NeuroImage 53, 1197–1207.
Zalesky, A., Fornito, A., Seal, M.L., Cocchi, L., Westin, C.F., Bullmore, E.T., Egan, G.F.,
Pantelis, C., 2011. Disrupted axonal fiber connectivity in schizophrenia. Biol.
Psychiatry 69, 80–89.
Zalonis, I., Bonakis, A., Christidi, F., Vagiakis, E., Papageorgiou, S.G., Kalfakis, N., Manta,
P., Vassilopoulos, D., 2010. Toward understanding cognitive impairment in patients
with myotonic dystrophy type 1. Arch. Clin. Neuropsychol. 25, 303–313.
Zanigni, S., Evangelisti, S., Giannoccaro, M.P., Oppi, F., Poda, R., Giorgio, A., Testa, C.,
Manners, D.N., Avoni, P., Gramegna, L.L., De Stefano, N., Lodi, R., Tonon, C., Liguori,
R., 2016. Relationship of white and gray matter abnormalities to clinical and genetic
features in myotonic dystrophy type 1. Neuroimage Clin. 11, 678–685.
Zwiers, M.P., 2010. Patching cardiac and head motion artefacts in diffusion-weighted
images. NeuroImage 53, 565–575.
M. van Dorst et al. NeuroImage: Clinical 21 (2019) 101615
10
